389890-42-0

Basic information

• Product Name: (TRANS)-3-AMINOCYCLOBUTANOL
• Synonyms: (1R,3R)-3-aMinocyclobutanol;trans-1-Amino-3-hydroxycyclobutane,N-BOCprotected;trans-3-(Boc-amino)-cyclobutanol;(TRANS)-3-AMINOCYCLOBUTANOL;Carbamic acid, (trans-3-hydroxycyclobutyl)-, 1,1-dimethylethyl ester (9CI);trans-3-AMintocyclobutanol;trans-tert-Butyl 3-hydrox...;Carbamic acid, N-(trans-3-hydroxycyclobutyl)-, 1,1-dimethylethyl ester
• CAS NO: 389890-42-0
• Molecular Formula: C₉H₁₇NO₃
• Molecular Weight: 187.23618
• Product Categories: MFCD09029039 oldold;1036260-45-3 oldold;N-BOC
• Mol File: 389890-42-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 112 °C
• Boiling Point: 303.7±31.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.19±0.40(Predicted)
• CAS DataBase Reference: (TRANS)-3-AMINOCYCLOBUTANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (TRANS)-3-AMINOCYCLOBUTANOL(389890-42-0)
• EPA Substance Registry System: (TRANS)-3-AMINOCYCLOBUTANOL(389890-42-0)

Safety Data

• Hazardous Substances Data: 389890-42-0(Hazardous Substances Data)

Usage

General Description

(TRANS)-3-aminocyclobutanol is a chemical compound that belongs to the class of aminocyclobutanol derivatives, which are characterized by a four-membered cyclobutane ring with an amino group attached. (TRANS)-3-AMINOCYCLOBUTANOL can exist in different stereoisomeric forms, with the "trans" configuration referring to the relative positioning of the amino group and the hydroxyl group. (TRANS)-3-aminocyclobutanol has potential applications in organic synthesis, particularly in the development of new pharmaceuticals and biologically active compounds. Its unique structure and properties make it an interesting target for research and drug discovery efforts. Additionally, its small and rigid cyclobutane ring may confer specific biological activities, making it a valuable scaffold for the design of new therapeutic agents.

Upstream product

• 1036260-45-3 trans-3-hydroxycyclobutanamine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 871014-16-3 trans-3-[(tert-butoxycarbonyl)amino]cyclobutyl 4-nitrobenzoate 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 1205037-95-1 (1r,3r)-3-aminocyclobutan-1-ol hydrochloride 
• 389890-43-1 tert-butyl (1,3-cis)-N-(3-hydroxycyclobutyl)carbamate 

Downstream Products

• 1458653-34-3 tert-butyl cis-3-(4-bromo-3,5-dimethylphenoxy)cyclobutylcarbamate 
• 1033710-17-6 3-(methylamino)cyclobutanol 
• 1392804-89-5 tert-butyl ((1r,3r)-3-hydroxycyclobutyl)(methyl)carbamate 
• 1205037-95-1 (1r,3r)-3-aminocyclobutan-1-ol hydrochloride 
• 1119284-93-3 trans-3-(tert-butoxycarbonylamino)cyclobutyl 4-methylbenzenesulfonate 

Relevant articles and documents

Novel CDK inhibitory compounds, preparation method thereof, pharmaceutical composition for use in preventing or treating CDK relating diseases containing the same as an active ingredient

The present invention relates to a novel CDK inhibitory compound, a method for manufacturing the same, and a pharmaceutical composition for preventing or treating a CDK-related disease containing the compound as an active ingredient. The novel CDK inhibit

INHIBITORS OF THE TEC KINASE ENZYME FAMILY

The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.

COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).